Corrected: BRIEF-Onxeo H1 net loss narrows to 11.2 million euros (July 28)

Valerio Therapeutics SA

29/07/2016 12:44

(Removes reference to Livatag in headline of July 28 brief 
item) 
    July 29 (Reuters) - Onxeo SA  C4X.PA : 
    * H1 net loss of 11.2 million euros ($12.40 million) versus 
loss of 11.3 million euros year ago 
    * H1 revenue 1.8 million euros versus 1.5 million euros year 
ago 
    * Livatag phase III trial in HCC: 80 pct of patients 
randomized 
    * First development steps of new oral formulation of 
Beleodaq 
    * 19.6 million euros cash-on-hand as of June 30, 2016 
 
Source text for Eikon:  ID:nBw8bntkya  
Further company coverage:  C4X.PA  
 
($1 = 0.9033 euros) 
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))